CymaBay Therapeutics (CBAY) Misses Q3 EPS by 3c

CymaBay Therapeutics (NASDAQ: CBAY) reported Q3 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29).

For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS says bull market has further to run
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results